ClinicalTrials.Veeva

Menu

Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status

Completed

Conditions

Neoplasms

Treatments

Other: PROMIS Physical Function Items
Other: Qualitative Interviews

Study type

Observational

Funder types

Industry
Other

Identifiers

Details and patient eligibility

About

The objective of this study is to conduct in-person qualitative interviews of subjects who have different tumor types to identify and assess relevant PROMIS physical function items that can be utilized in future studies. Health Research Associates (HRA) will conduct qualitative interviews in subjects with a variety of cancer types. PROMIS is a set of self-report measurement tools, developed by the United States (US) National Institutes for Health (NIH). The most recent version of PROMIS Physical Function Item Bank contains 165 items assessing a range of abilities and its subset, a 45-item PROMIS Function Cancer Item Bank which contains questions relevant to subjects with cancer. Approximately 150 subjects with five tumor types will be recruited. HRA will conduct the interviews that will be audio-recorded for transcription and analysis. Five tumor types that will be focused on are Breast, Prostate, Non-Small-Cell Lung Cancer (NSCLC), Multiple Myeloma, and Diffuse Large B-Cell (DLBCL) or Follicular Lymphoma. Interviews will be conducted in English language in private areas within clinic site or rented meeting facilities and will last approximately for 60-90 minutes.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject has a confirmed diagnosis of a primary tumor of one of the following: Breast Cancer, Prostate Cancer, NSCLC, Multiple Myeloma (excluding smoldering/asymptomatic multiple myeloma) and DLBCL or Follicular Lymphoma
  • Subject is able to read, write, and speak English well enough to understand and complete Informed Consent Form (ICF) and take part in the interview process
  • Subject has received treatment for their qualifying tumor within the prior 6 months, with the exception of treatment-naïve subjects who have been diagnosed within the past 6 months
  • Subject is at least 18 years of age
  • Subject has an estimated life expectancy of 3 months or greater

Exclusion criteria

  • Subject has more than one current primary tumor
  • Subject has a Stage 0 or in situ neoplasm
  • Subject has known unstable and/or untreated brain metastasis
  • Subject had major surgery within the last 30 days prior to enrolment that may be associated with changes in physical function. Open biopsy is considered a major surgery
  • Subject has a current or past history of a personality disorder, bipolar disorder, schizophrenia or other psychotic disorder, obsessive compulsive disorder, cognitive disorder, post-traumatic stress disorder, or other mental deficit
  • In the opinion of the site investigator or study director, subject has any medical condition or disorder that could compromise his/her ability to give written informed consent and/or prevent or interfere with the Subject's ability to successfully participate in a face-to-face interview and provide meaningful and non-confounded information about their experience with their qualifying tumor

Trial design

1 participants in 5 patient groups

Subjects with breast cancer
Description:
Approximately 30 subjects who have confirmed diagnosis of breast cancer will be included in the study
Treatment:
Other: Qualitative Interviews
Other: PROMIS Physical Function Items
Subjects with prostate cancer
Description:
Approximately 30 subjects who have confirmed diagnosis of prostate cancer will be included in the study
Treatment:
Other: Qualitative Interviews
Other: PROMIS Physical Function Items
Subjects with NSCLC
Description:
Approximately 30 subjects who have confirmed diagnosis of NSCLC will be included in the study
Treatment:
Other: Qualitative Interviews
Other: PROMIS Physical Function Items
Subjects with multiple myeloma
Description:
Approximately 30 subjects who have confirmed diagnosis of multiple myeloma excluding smoldering/asymptomatic multiple myeloma will be included in the study
Treatment:
Other: Qualitative Interviews
Other: PROMIS Physical Function Items
Subjects with DLBCL or follicular lymphoma
Description:
Approximately 30 subjects who have confirmed diagnosis of DLBCL or follicular lymphoma will be included in the study
Treatment:
Other: Qualitative Interviews
Other: PROMIS Physical Function Items

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems